Development and validation of a workflow to conduct virtual bioequivalence studies using pbbm- pbpk models
Ended Cooperative Agreement Awarded Last action
- Award ID
- U01FD007906
- Recipient
-
Simulations Plus Inc. UEI MZN6WDBMXN24
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $748,424
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Originally
- Funding agency
- Center for Drug Evaluation and Research Food and Drug Administration, Department of Health and Human Services
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- This project aims to define and validate a workflow to demonstrate bioequivalence using in silico mechanistic models. The offerors decided to focus on pbbm-pbpk models and will use two separate software to perform the analysis: gastroplus© and PK-SIM©. By doing so, advantages, limitations, and gaps will be identified across leading platforms used to describe the adme of apis. This goal will be achieved through three elements: (1) identification of case studies in the university of maryland and other partners' databases; (2) validation of the ability of gastroplus and PK-SIM to predict the inter- and intrasubject variability; (3) simulation of informative scenario to support the establishment of the virtual bioequivalence workflow in collaboration with FDA scientist. Case studies' datasets will support the development and validation of pbbm-pbpk models for multiple apis on both platforms. Then, virtual populations simulation will be compared with observed individual PK concentration time courses to assess the ability of both platforms to describe the clinically observed intersubject variability. Based on the results, quantifiable validation criteria will be developed. Those will serve as a checkpoint in the workflow before conducting any virtual bioequivalence study. The pbbm-pbpk models will then be used to perform multiple virtual bioequivalence studies, and the results will be compared with either positive or negative case studies from collaborators' datasets. Informative scenarios will be simulated to support the development of the workflow based on drug product characteristics (e.g., high variability, narrow therapeutic index). Furthermore, the integration of intrasubject variability in the workflow will be tested. The findings from this project will support the regulatory assessment of generic drug products. The developed and validated workflow will help to establish scientific and regulatory standards for supporting innovative development and performing virtual bioequivalence evaluation of these generic drug products.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $249,392 | |
| Amendment | $249,392 | |
| Original award | $249,640 |
Quick answers
Who received award U01FD007906?
U01FD007906 was awarded to Simulations Plus Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 5, 2023.
How much is award U01FD007906 worth?
$748,424 has been obligated on U01FD007906.
Which agency awarded U01FD007906?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded U01FD007906, with funding from Center for Drug Evaluation and Research (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award